A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Trial Profile

A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs E6 TCR (Primary) ; Aldesleukin
  • Indications Cervical intraepithelial neoplasia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2017 Planned initiation date changed from 16 Oct 2017 to 18 Oct 2017.
    • 07 Oct 2017 Planned initiation date changed from 6 Oct 2017 to 16 Oct 2017.
    • 03 Oct 2017 Planned initiation date changed from 26 Sep 2017 to 6 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top